Oarsman Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-350
| Closed | -$32.3K | – | 476 |
|
|
2024
Q4 | $32.3K | Sell |
350
-141
| -29% | -$12.7K | 0.01% | 522 |
|
|
2024
Q3 | $41.2K | Buy |
+491
| New | +$37.5K | 0.01% | 483 |
|
|
2021
Q1 | – | Sell |
-3,525
| Closed | -$205K | – | 190 |
|
|
2020
Q4 | $205K | Sell |
3,525
-270
| -7% | -$16.3K | 0.08% | 172 |
|
|
2020
Q3 | $240K | Sell |
3,795
-125
| -3% | -$8.67K | 0.11% | 142 |
|
|
2020
Q2 | $302K | Buy |
3,920
+564
| +17% | +$43.2K | 0.15% | 121 |
|
|
2020
Q1 | $251K | Sell |
3,356
-1,710
| -34% | -$118K | 0.23% | 92 |
|
|
2019
Q4 | $329K | Sell |
5,066
-805
| -14% | -$52.4K | 0.15% | 133 |
|
|
2019
Q3 | $372K | Sell |
5,871
-433
| -7% | -$28.3K | 0.18% | 123 |
|
|
2019
Q2 | $426K | Sell |
6,304
-464
| -7% | -$30.5K | 0.19% | 113 |
|
|
2019
Q1 | $440K | Sell |
6,768
-20,249
| -75% | -$1.35M | 0.21% | 111 |
|
|
2018
Q4 | $1.69M | Sell |
27,017
-2,827
| -9% | -$198K | 0.87% | 38 |
|
|
2018
Q3 | $2.3M | Sell |
29,844
-762
| -2% | -$57.5K | 0.93% | 35 |
|
|
2018
Q2 | $2.17M | Sell |
30,606
-2,018
| -6% | -$143K | 0.99% | 33 |
|
|
2018
Q1 | $2.46M | Sell |
32,624
-1,445
| -4% | -$115K | 1.12% | 27 |
|
|
2017
Q4 | $2.44M | Sell |
34,069
-1,438
| -4% | -$109K | 1.05% | 29 |
|
|
2017
Q3 | $2.88M | Buy |
35,507
+558
| +2% | +$42.7K | 1.22% | 26 |
|
|
2017
Q2 | $2.47M | Buy |
34,949
+378
| +1% | +$25.2K | 1.13% | 27 |
|
|
2017
Q1 | $2.35M | Buy |
34,571
+8,578
| +33% | +$603K | 1.09% | 30 |
|
|
2016
Q4 | $1.86M | Sell |
25,993
-8,371
| -24% | -$622K | 1.2% | 24 |
|
|
2016
Q3 | $2.72M | Buy |
34,364
+9,391
| +38% | +$763K | 1.39% | 17 |
|
|
2016
Q2 | $2.08M | Buy |
24,973
+2,948
| +13% | +$262K | 1.08% | 27 |
|
|
2016
Q1 | $2.02M | Buy |
22,025
+684
| +3% | +$61.7K | 1.08% | 29 |
|
|
2015
Q4 | $2.16M | Buy |
21,341
+205
| +1% | +$21.3K | 1.21% | 21 |
|
|
2015
Q3 | $2.08M | Buy |
21,136
+47
| +0.2% | +$5.22K | 1.23% | 22 |
|
|
2015
Q2 | $2.47M | Sell |
21,089
-9
| -0% | -$983 | 1.68% | 8 |
|
|
2015
Q1 | $2.07M | Buy |
21,098
+395
| +2% | +$40.1K | 1.43% | 12 |
|
|
2014
Q4 | $1.95M | Buy |
20,703
+1,201
| +6% | +$124K | 1.41% | 15 |
|
|
2014
Q3 | $2.08M | Buy |
19,502
+297
| +2% | +$29.1K | 1.53% | 12 |
|
|
2014
Q2 | $1.59M | Buy |
19,205
+3,075
| +19% | +$239K | 1.16% | 20 |
|
|
2014
Q1 | $1.14M | Buy |
+16,130
| New | +$1.27M | 0.88% | 36 |
|
Other funds holding GILD
Oarsman Capital's GILD Position: Q1 2025 in Review
Oarsman Capital sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 350 shares — an estimated $32.3K sold.
Oarsman Capital first reported a position in GILD in Q1 2014 and held it in 30 quarters. The position peaked at $2.88M in Q3 2017. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.
- Oarsman Capital reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
- Oarsman Capital sold 350 Gilead Sciences shares in Q1 2025, an estimated $32.3K.
- Oarsman Capital first reported a position in Gilead Sciences in Q1 2014 and held it in 30 quarters.
- Oarsman Capital's Gilead Sciences position peaked at $2.88M in Q3 2017.
- 2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.
Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.